McDonald's vs. Pfizer - The Better Retirement Stock Isn't the One You'd Guess

McDonald's Corporation (NYSE:MCD) and Pfizer Inc. (NYSE:PFE) often appear in retirement portfolios because both look dependable. Yet each has trailed the broader market in recent years, raising questions about whether reputation is masking weaker performance.

Pfizer offers a dividend yield near 7%, while McDonald's has raised its payout annually for nearly five decades. If you are using this year's volatility to check up on your financial health, this comparison can help clarify the choice. We score both stocks on current income, growth prospects, and dividend reliability before deciding which may be the stronger retirement holding today.

How both blue chips arrived here bruised

Both stocks have lagged the broader market. Pfizer delivered a total shareholder return of negative 42.2% over the three years ended December 2025 and negative 13.6% over five years, according to its 2026 proxy statement, as the COVID franchise faded and patent worries mounted.

McDonald's is down about 12% year to date in 2026 and 6% over the past year, according to 24/7 Wall St., with earnings pressured by a softer low-income consumer and franchise-level margin strains. In both cases, the "safe" label may be doing more work than the tape suggests.

Which stock pays more income today?

At today's prices, Pfizer looks like the runaway leader on current yield. The drugmaker pays $1.72 a share annually, or about 7.0% at recent trading levels, according to Yahoo Finance, while McDonald's pays $7.44 a share for a yield closer to 2.7%, according to Dividend.com.

On a $10,000 buy, that is roughly $700 versus $270 in the first year. For a retiree drawing on portfolio income, that gap is real. Pfizer's yield has ballooned because the stock has slid since the COVID vaccine boom faded.

Which dividend has been growing faster?

McDonald's lifted its quarterly payout by 5% in October 2025, its 49th straight annual increase, according to the company. Pfizer's 2025 dividend rose just 2.4% from the year before, according to its 2026 proxy statement. That gap widens over time as McDonald's has grown its dividend at a roughly 10% compound rate over the past five years, according to Stock Events.

Pfizer's slower growth reflects a shrinking COVID business and looming patent expirations on drugs including Eliquis and Ibrance. Round two goes to McDonald's.

Which payout looks more reliable?

Pfizer's dividend eats up more than 100% of trailing earnings, according to stock data provider MerryDiv, meaning the payout has recently outstripped what the business earned. Management's 2026 adjusted EPS guidance of $2.80 to $3.00 would cover the $1.72 dividend roughly 1.6 times, according to Pfizer's SEC filings.

Why McDonald's payout looks steadier

McDonald's tells a different story:

• 49 straight years of dividend increases, closing in on Dividend King status
• A payout ratio near 59.5%, leaving room to keep raising
• Steady free cash flow from a franchise-heavy business model

The overall verdict for retirement investors

Pfizer wins on current yield, while McDonald's wins on growth and reliability. In a match scored by rounds, the fast-food giant takes it two-to-one, even though the pharmaceutical name pays you more today.

For most retirees who need income to last decades rather than months, a growing, well-covered payout may matter more than a big yield built on shrinking earnings and a patent cliff. That is the case McDonald's makes on this scorecard, and why the "safe" retirement stock may not be the one at the top of your dividend screener.

When Pfizer's high yield may justify the risk

None of this means Pfizer is a bad stock for every retirement holding. If you draw income now, keep a diversified portfolio, and are comfortable taking a specific risk on a single name, its 7% yield may still play a role as a small, income-focused slice rather than a core position.

Some Wall Street analysts stay bullish: Argus recently moved Pfizer to Buy with a $35 target, citing its GLP-1 pipeline and oncology growth. Others, including RBC Capital, rate it Underperform at $25, citing an "insurmountable" revenue cliff through 2030.

Bottom line

McDonald's wins this comparison because its dividend keeps growing and appears safer over a long retirement horizon. Pfizer's 7% yield is attractive, but declining COVID revenue, major patent expirations through 2030, and a payout ratio above 100% of trailing earnings raise concerns about its durability.

If you are ready to start investing with retirement in mind, the better question is not which stock pays more today, but which company can keep paying and raising dividends for decades. That favors steady, cash-generative businesses like McDonald's. Pfizer may still suit a small satellite position within a broadly diversified retirement portfolio.